Rebuttal from Dr Rho et al
- PMID: 24798833
- PMCID: PMC4011656
- DOI: 10.1378/chest.14-0115
Rebuttal from Dr Rho et al
Comment on
-
Point: were industry-sponsored roflumilast trials appropriate? Yes.Chest. 2014 May;145(5):937-9. doi: 10.1378/chest.14-0112. Chest. 2014. PMID: 24798830 No abstract available.
References
-
- Suissa S, Rabe KF. Point: were industry-sponsored roflumilast trials appropriate? Yes. Chest. 2014;145(5):937-939 - PubMed
-
- Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD002309 - PubMed
-
- Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2013;7(1):13-24 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
